Co-Diagnostics AI Stock Analysis
Want to see CODX full AI Analyst Report?
Co-Diagnostics (CODX) AI Stock Analysis
Co-Diagnostics
(NASDAQ:CODX)
CODX scores low primarily due to severely weakened financial performance (minimal revenue, large losses, and heavy cash burn with a shrinking capital base) and very bearish technicals (price far below major moving averages with negative momentum). Operational progress discussed on the earnings call provides some upside optionality, but near-term liquidity needs and potentially dilutive financing/govemance frictions keep overall risk elevated.
Co-Diagnostics (CODX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.93M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.98M
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 3.00
- Revenue Growth
- 28.89%
- EPS Growth
- 34.53%
- Country
- US
- Employees
- 115
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Co-Diagnostics Business Overview & Revenue Model
Company Description
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internat...
Co-Diagnostics Earnings Call Summary
The call conveyed meaningful operational and regulatory progress — including a dual FDA submission for an upper respiratory multiplex assay, >1,400-patient clinical enrollment, >10,000 analytical PCR runs, TB program advancement toward ERPD, a blood-based Ebola proof-of-concept, strengthened international manufacturing partnerships, and reduced operating expenses that improved net loss and adjusted EBITDA. However, these positives are counterbalanced by a very low revenue base ($166K), a steep decline in cash to $3.6M (≈70% drop), continued operating losses, and materially reduced total assets. While execution milestones materially de-risk the technology and regulatory path, the company faces near-term liquidity and commercialization scaling risks.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management's guidance emphasized continued near‑term operating losses while advancing toward commercialization and prioritizing regulatory, clinical, commercial and platform milestones; Q2 FY2026 results included revenue of $166k (vs. $163k), cost of revenue $45k, gross profit ≈$121k (vs. $131k), operating expenses $6.3M (vs. $8.2M), R&D $4.2M (vs. $4.7M), sales & marketing $467k (vs. $610k), G&A $1.5M (vs. $2.6M), net loss $6.3M or $1.46 per share (vs. $7.7M or $7.00), adjusted EBITDA loss $5.8M (vs. $7.2M), cash $3.6M (vs. $11.9M at 2025 year‑end), total assets $16.6M and liabilities $3.9M; operational metrics and milestones include 27 analytical studies and >10,000 upper‑respiratory PCR runs, enrollment of >1,400 symptomatic patients across 9 U.S. sites, submission of a dual 510(k)/CLIA‑waived Flu A/B+RSV application, planned TB submissions to India’s CDSCO and WHO ERPD later this year, a C‑CAMP request for 200 Bundibugyo tests, cloud expansion to India and Saudi Arabia, and ongoing evaluation of equity, debt, strategic transactions and nondilutive funding to support these objectives.
Co-Diagnostics Financial Statement Overview
Summary
Overall fundamentals are very weak: revenue has collapsed from 2021 and remains minimal, profitability is deeply negative (including negative TTM gross profit), and cash flow shows persistent, material operating and free-cash-flow burn. A modest positive is low leverage, but the equity and asset base has eroded sharply, increasing financing and execution risk.
Income Statement
14Very NegativeBalance Sheet
45NeutralCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 858.89K | 622.49K | 3.92M | 6.81M | 34.22M | 97.89M |
| Gross Profit | -81.37K | 400.11K | 2.92M | 2.63M | 28.74M | 86.31M |
| EBITDA | -46.84M | -47.41M | -36.20M | -36.88M | -10.31M | 45.97M |
| Net Income | -47.48M | -46.90M | -37.64M | -35.33M | -14.24M | 36.66M |
Balance Sheet | ||||||
| Total Assets | 12.79M | 24.74M | 64.00M | 95.32M | 123.09M | 160.03M |
| Cash, Cash Equivalents and Short-Term Investments | 714.80K | 11.88M | 29.75M | 58.55M | 81.26M | 89.86M |
| Total Debt | 1.56M | 1.24M | 2.15M | 2.99M | 347.92K | 0 |
| Total Liabilities | 3.37M | 4.11M | 9.69M | 9.31M | 8.57M | 25.56M |
| Stockholders Equity | 9.43M | 20.63M | 54.31M | 86.01M | 114.52M | 134.48M |
Cash Flow | ||||||
| Free Cash Flow | -27.19M | -29.84M | -29.90M | -23.45M | 5.14M | 40.41M |
| Operating Cash Flow | -26.88M | -29.14M | -29.16M | -22.08M | 6.57M | 41.08M |
| Investing Cash Flow | -654.72K | 26.27M | 17.07M | 15.39M | -58.17M | 4.10M |
| Financing Cash Flow | 16.81M | 11.81M | 103.91K | -1.36M | -14.03M | 450.40K |
Co-Diagnostics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CODX, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.42, below the 50-day MA of 0.80, and below the 200-day MA of 2.07, indicating a bearish trend. The MACD of -0.17 indicates Negative momentum. The RSI at 23.80 is Positive, neither overbought nor oversold. The STOCH value of 15.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CODX.
Co-Diagnostics Risk Analysis
Co-Diagnostics disclosed 23 risk factors in its most recent earnings report. Co-Diagnostics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksCo-Diagnostics Peers Comparison
Overall Rating
HSCS40Underperform
SINT40Underperform
VVOS40Underperform
CODX40Underperform
ALUR39Underperform
ADGM37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 40Underperform | $10.56M | -0.66 | -816.25% | ― | -27.70% | 61.44% | |
| 40Underperform | $10.17M | -0.60 | -309.86% | ― | 160.79% | 67.55% | |
| 40Underperform | $3.29M | -0.05 | 2616.82% | ― | 45.21% | -10.29% | |
| 40Underperform | $2.72M | -0.01 | -322.92% | ― | 28.89% | 34.53% | |
| 39Underperform | $2,001 | 0.00 | 44.17% | ― | -55.49% | 21.55% | |
| 37Underperform | $1.77M | -0.04 | -661.85% | ― | -100.00% | 70.33% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CODX | Co-Diagnostics | 0.26 | -9.23 | -97.28% | |
| SINT | Sintx Technologies | 1.34 | -2.15 | -61.46% | |
| VVOS | Vivos Therapeutics, Inc. | 0.10 | -2.29 | -95.90% | |
| ADGM | Adagio Medical Holdings, Inc | 1.93 | -21.17 | -91.65% | |
| ALUR | Allurion Technologies, Inc. | 0.02 | -20.98 | -99.90% | |
| HSCS | Heart Test Laboratories, Inc. | 2.13 | -0.88 | -29.17% |
Co-Diagnostics Corporate Events
Co-Diagnostics Plans Special Meeting After Quorum Shortfalls
NegativeCo-Diagnostics, Inc. disclosed that it was unable to conduct business at its Annual Meeting of Stockholders originally held on September 3, 2026, because a quorum was not present or represented. The meeting was adjourned and reconvened on September 2...
Co-Diagnostics Secures Convertible Financing to Bolster Liquidity
NegativeOn October 9, 2026, Co-Diagnostics entered into a senior secured convertible loan agreement with J.J. Astor & Co. for up to $3.1 million in funding, receiving $2.1 million at closing and the ability to draw an additional $1.0 million subject to condi...
Co-Diagnostics Faces Repeated Annual Meeting Quorum Delays
NegativeCo-Diagnostics, Inc. reported that its Annual Meeting of Stockholders originally held on September 3, 2026, did not achieve a quorum, preventing any business from being conducted and prompting an adjournment to September 24, 2026. When the adjourned...
Co-Diagnostics Highlights PCR Platform and Global Partnerships
PositiveOn September 16, 2026, Co-Diagnostics, Inc. plans to host an investor and analyst presentation highlighting its collaboration with ReadyGo Diagnostics Ltd., its Co-Dx PCR platform, and associated development and manufacturing initiatives, including i...
Co-Diagnostics partners on blood-based PCR Ebola testing
PositiveOn September 16, 2026, Co-Diagnostics and ReadyGo Diagnostics announced a collaboration to evaluate combining the Co-Dx PCR platform with ReadyGo’s GoCollect blood sample-preparation system for point-of-need molecular testing. The initial application...
Co-Diagnostics Tests ReadyGo Tech for PCR Platform
NeutralIn August 2026, Co-Diagnostics entered into a material transfer agreement with ReadyGo Diagnostics to assess the compatibility of ReadyGo’s sample collection and preparation technologies with the Co-Dx PCR platform. ReadyGo’s materials are designed t...
Co-Diagnostics Appoints New Principal Financial Officer
NeutralOn September 2, 2026, Co-Diagnostics, Inc. announced that Chief Financial Officer Brian Brown’s employment ended on that date, concluding his tenure as principal financial and accounting officer. Effective the same day, Executive Vice President of Fi...
Co-Diagnostics Adjourns Annual Meeting, Sets New Date
NegativeCo-Diagnostics, Inc. held its previously announced Annual Meeting of Stockholders on September 3, 2026, but the meeting failed to reach a quorum and therefore could not conduct any formal business. Under the company’s bylaws, the chairperson adjourne...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026
